influenza
pandem
pose
seriou
threat
human
anim
incur
great
financi
societ
cost
decad
common
pathogen
caus
influenza
human
type
influenza
virus
season
pandem
type
b
influenza
virus
convent
treatment
diseas
includ
two
class
antivir
ion
channel
blocker
adamantan
amantadin
rimantadin
neuraminidas
na
inhibitor
oseltamivir
peramivir
zanamivir
laninamivir
ison
lee
yen
two
categori
design
target
viral
protein
therebi
interf
viru
infect
mechan
howev
emerg
new
influenza
viral
strain
carri
drug
resist
mutat
outpac
develop
pathogentarget
antivir
present
major
clinic
challeng
circul
influenza
virus
show
resist
adamantan
ison
jackson
et
al
lee
yen
moscona
intrins
resist
compound
also
observ
influenza
b
ison
addit
begin
influenza
season
circul
season
virus
possess
oseltamivir
resist
mutat
observ
lackenbi
et
al
sinc
first
report
case
pandem
oseltamivirresist
variant
strain
also
identifi
baz
et
al
leung
et
al
speer
et
al
storm
et
al
rapid
develop
antivir
resist
highlight
need
altern
therapeut
strategi
influenza
viru
rna
viru
undergo
rapid
mutat
select
pressur
drug
use
pathogentarget
antivir
drug
interact
specif
viral
enzym
therefor
render
ineffect
mutant
popul
contrast
hosttarget
therapeut
interven
infect
pathway
offer
sustain
therapeut
potenti
regardless
viral
mutat
fusion
virus
host
cellular
endosom
membran
facilit
low
endosom
ph
stertz
shaw
major
event
influenza
infect
cascad
vacuolar
atpas
vatpas
activ
respons
pump
proton
endosom
compart
identifi
requir
influenza
viru
replic
previou
studi
guinea
carrasco
muller
et
al
perez
carrasco
vatpaseencod
gene
also
identifi
sever
genomewid
screen
host
factor
regul
influenza
viru
replic
knockdown
vatpas
subunit
shown
result
signific
inhibit
influenza
viru
replic
chin
brass
hao
et
al
karla
et
al
konig
et
al
mehl
doudna
block
vatpas
activ
therefor
present
opportun
imped
influenza
infect
prevent
low
phdepend
membran
fusion
endosom
virion
addit
influenza
virus
flavivirus
pierson
diamond
vaccinia
virus
townsley
et
al
rhabdovirus
albertini
et
al
coronavirus
belouzard
et
al
also
enter
target
cell
phdepend
fashion
diphyllin
natur
compound
isol
cleistanthu
collinu
recent
identifi
novel
vatpas
inhibitor
inhibit
lysosom
acidif
human
osteoclast
sorensen
et
al
reduc
vatpas
express
gastric
adenocarcinoma
cell
shen
et
al
studi
aim
character
applic
diphyllin
antivir
variou
influenza
viru
strain
two
type
cell
line
bafilomycin
macrolid
antibiot
specif
inhibitor
vacuolar
atpas
inhibit
growth
type
type
b
human
influenza
virus
mdck
cell
ochiai
et
al
includ
key
function
assay
control
addit
combinatori
effect
diphyllin
pathogentarget
therapeut
includ
oseltamivir
amantadin
assess
evalu
diphyllin
potenti
enhanc
exist
influenza
therapi
diphyllin
chembridg
san
diego
ca
charlton
et
al
fukamiya
lee
dissolv
dimethyl
sulfoxid
dmso
fisher
scientif
oseltamivir
carboxyl
amantadin
hydrochlorid
sigma
dissolv
steril
water
three
compound
mm
primari
stock
lm
work
stock
made
respect
solvent
store
bafilomycin
sigma
dissolv
dmso
make
lm
work
stock
right
experi
compound
freshli
dilut
cultur
media
achiev
desir
concentr
mardindarbi
canin
kidney
mdck
cell
cell
atcc
maintain
dmem
supplement
fetal
bovin
serum
unitsml
penicillin
lgml
streptomycin
influenza
viru
infect
experi
mdck
cell
cell
overlaid
dmem
supplement
bsa
mm
hepe
buffer
lgml
tpcktreat
trypsin
reagent
cell
cultur
purchas
invitrogen
incub
infect
step
carri
co
unless
otherwis
specifi
viru
background
manicassami
et
al
kindli
provid
dr
aldolfo
garciasastr
mount
sinai
school
medicin
new
york
two
refer
influenza
viru
strain
b
purchas
atcc
addit
three
human
influenza
viru
isol
asan
asan
asan
use
studi
avian
influenza
viru
isol
duck
yilan
taiwan
type
influenza
virus
propag
mdck
cell
titrat
plaqu
assay
previous
describ
szretter
et
al
dengu
viru
serotyp
strain
tripleplaquepurifi
clone
clinic
isol
cultur
titrat
plaqu
assay
previous
describ
yauch
et
al
vitro
cytotox
assay
diphyllin
mdck
cell
cell
grown
clear
polystyren
micropl
corn
densiti
cell
per
well
day
prior
experi
diphyllin
twofold
serial
dilut
cell
media
ad
cell
monolay
four
replic
final
dmso
concentr
well
day
cultur
supernat
remov
mtt
reagent
bromid
mgml
pb
ad
well
incub
h
next
mtt
remov
dmso
ad
well
solubil
purpl
formazan
crystal
absorb
valu
measur
nm
refer
wavelength
nm
tecan
infinit
reader
tecan
group
switzerland
control
cell
well
without
diphyllin
treatment
assum
repres
cell
viabil
normal
cell
viabil
data
plot
diphyllin
concentr
fit
nonlinear
regress
curv
use
graphpad
prism
graphpad
softwar
san
diego
ca
cytotox
concentr
cc
concentr
diphyllin
cellular
viabil
reduc
obtain
accordingli
confluent
cultur
mdck
cell
cell
black
polystyren
clear
bottom
micropl
corn
incub
bafilomycin
variou
concentr
diphyllin
four
replic
min
acridin
orang
lgml
media
molecular
probe
distribut
well
incub
addit
min
wash
fluoresc
imag
obtain
data
quantifi
ici
research
imag
cytomet
compucyt
westwood
use
nm
nm
emiss
filter
green
fluoresc
nm
nm
emiss
filter
red
fluoresc
mdck
cell
seed
plate
cellswel
day
experi
obtain
cultur
confluenc
diphyllin
lm
ad
cell
three
differ
time
point
rel
viru
infect
h
prior
infect
time
infect
h
infect
untreat
well
use
control
experi
viru
multipl
infect
moi
use
infect
cell
period
infect
test
cell
wash
overlaid
fresh
media
contain
lm
diphyllin
h
cell
wash
lyse
analyz
viral
nucleoprotein
np
express
use
western
blot
section
follow
method
regard
cellular
incub
diphyllin
viru
infect
use
throughout
studi
examin
antivir
effect
diphyllin
variou
concentr
diphyllin
ad
monolay
mdck
cell
h
prior
infect
human
influenza
virus
moi
avian
influenza
viru
moi
mdck
cell
use
period
infect
cell
wash
overlaid
fresh
media
contain
concentr
diphyllin
previou
step
incub
anoth
h
h
avian
influenza
viru
infect
cell
without
diphyllin
treatment
use
control
next
cell
either
fix
fluoresc
microscopi
examin
gfp
express
section
lyse
realtim
quantit
rtpcr
section
western
blot
section
addit
cell
cultur
supernat
test
well
harvest
determin
viru
titer
tissu
cultur
infecti
dose
tcid
assay
hemagglutin
ha
test
influenza
virus
section
plaqu
assay
section
cpe
inhibit
assay
use
determin
ic
compound
concentr
compound
show
inhibit
virusinduc
cpe
variou
influenza
viru
strain
briefli
mdck
cell
seed
micropl
cellswel
day
experi
obtain
confluenc
test
diphyllin
amantadin
serial
dilut
compound
ad
mdck
cell
h
prior
viru
infect
moi
moi
use
strain
period
infect
test
well
wash
overlaid
fresh
media
contain
ident
compound
concentr
previou
step
oseltamivir
instead
pretreat
compound
ad
cell
period
infect
twentyfour
hour
later
cellular
viabil
examin
mtt
assay
describ
section
infect
cell
without
compound
treatment
assum
repres
cell
viabil
cell
without
infect
compound
treatment
assum
repres
cell
viabil
normal
cell
viabil
data
plot
diphyllin
concentr
fit
nonlinear
regress
curv
graphpad
prism
graphpad
softwar
gener
ic
antivir
activ
combin
diphyllin
vs
oseltamivir
diphyllin
vs
amantadin
test
use
treatment
protocol
describ
section
use
viru
strain
infect
respect
cell
harvest
np
express
analysi
use
western
blot
section
extracellular
viru
titer
supernat
determin
ha
test
section
addit
cpe
inhibit
assay
describ
section
conduct
examin
cell
protect
effect
cell
grown
micropl
corn
treat
diphyllin
bafilomycin
infect
viru
describ
section
cell
fix
paraformaldehyd
stain
dihydrochlorid
dapi
kpl
imag
use
deltavis
deconvolut
microscop
system
appli
precis
issaquah
wa
digit
imag
blue
green
fluoresc
acquir
use
dapi
fitc
filter
respect
imag
overlaid
deconvolut
use
softworx
softwar
experi
fluoresc
quantif
cell
grown
clear
bottom
black
polystyren
micropl
corn
gfp
fluoresc
intens
quantifi
use
imag
cytomet
ici
describ
section
infect
cell
without
compound
treatment
assum
repres
fluoresc
intens
cell
without
infect
compound
treatment
assum
repres
fluoresc
intens
normal
data
plot
diphyllin
concentr
total
rna
mdck
cell
cell
extract
use
rneasi
mini
kit
qiagen
viral
rna
cell
cultur
supernat
extract
use
qiaamp
viral
rna
mini
kit
rna
qiagen
accord
manufactur
manual
influenza
virus
realtim
quantit
rtpcr
perform
onestep
sybr
green
qrtpcr
kit
quanta
bioscienc
gaithersburg
md
use
previous
publish
primer
target
gene
influenza
viru
ward
et
al
canin
bactin
wang
et
al
briefli
reaction
mixtur
reversetranscrib
min
heat
min
underw
cycl
follow
firstderiv
melt
curv
analysi
abi
system
appli
biosystem
reaction
set
triplic
obtain
ct
valu
normal
bactin
rel
influenza
viru
gene
express
fold
chang
untreat
control
determin
method
livak
schmittgen
dengu
viru
probebas
quantit
rtpcr
perform
viru
titer
determin
base
genom
equival
ge
previous
describ
yauch
et
al
mdck
cell
cell
lyse
sd
sampl
buffer
invitrogen
disrupt
sonic
cell
lysat
protein
separ
nupag
bistri
gel
invitrogen
follow
manufactur
instruct
transfer
onto
lm
pore
size
pvdf
membran
immobilon
milipor
corp
protein
blot
probe
influenza
viru
antinp
antibodi
cultur
supernat
atcc
hybridoma
clone
antitubulin
antibodi
genscript
room
temperatur
hour
detect
protein
signal
membran
incub
sheep
antimous
igg
hrp
conjug
amersham
dilut
anoth
hour
develop
use
ecl
plu
western
blot
detect
reagent
kit
amersham
quantif
virus
tissu
cultur
infecti
dose
assay
hemagglutin
test
plaqu
assay
fifti
percent
tissu
cultur
infecti
dose
tcid
assay
hemagglutin
ha
test
perform
previous
describ
szretter
et
al
cultur
supernat
contain
influenza
virus
chicken
red
blood
cell
use
ha
test
avian
influenza
viru
guinea
pig
red
blood
cell
lonza
use
human
influenza
viru
strain
plaqu
assay
dengu
viru
conduct
previous
describ
yauch
et
al
throughout
studi
data
analyz
plot
use
graphpad
prism
graphpad
softwar
viral
titer
cell
viabil
compar
analysi
varianc
anova
follow
dunnett
multipl
comparison
test
error
bar
repres
standard
deviat
sd
valu
p
consid
signific
p
p
p
p
standard
mtt
assay
use
determin
cytotox
diphyllin
mdck
cell
cell
day
incub
cc
diphyllin
lm
mean
sd
mdck
cell
cell
respect
fig
weak
base
phsensit
dye
acridin
orang
use
studi
investig
effect
diphyllin
acidif
endosom
mdck
cell
cell
dye
taken
live
cell
acid
endosom
cell
stain
red
proton
acridin
orang
wherea
nonacid
endosom
stain
green
seen
fig
comparison
extens
redstain
endosom
untreat
cell
addit
bafilomycin
lm
diphyllin
lm
show
decreas
acid
endosom
increas
nonacid
endosom
cell
degre
inhibit
endosom
acidif
shown
correl
diphyllin
concentr
quantit
analyz
endosom
acidif
green
red
fluoresc
data
collect
diphyllintr
well
compar
greenr
fluoresc
ratio
evalu
indic
fig
diphyllin
treatment
result
dosedepend
quench
red
fluoresc
cytoplasm
vesicl
data
suggest
diphyllin
inhibit
endosom
acidif
mdck
cell
cell
studi
lm
diphyllin
ad
mdck
cell
three
differ
time
point
rel
viru
infect
incub
cell
h
infect
period
compar
untreat
control
diphyllin
treatment
infect
result
reduc
mrna
level
viral
matrix
gene
reduc
express
viral
np
cell
fig
furthermor
cellular
exposur
diphyllin
prior
viru
infect
result
maxim
inhibit
effect
viral
replic
base
western
blot
analysi
indic
diphyllin
treatment
effect
alter
cellular
suscept
viru
infect
pretreat
set
therefor
pretreat
method
appli
follow
experi
influenza
viru
appli
studi
investig
antivir
activ
diphyllin
intracellular
viral
mrna
protein
express
examin
absenc
presenc
diphyllin
pretreat
mdck
cell
cell
result
show
rel
level
influenza
viral
matrix
gene
mrna
decreas
presenc
lm
diphyllin
respect
compar
untreat
control
mdck
cell
also
indic
fig
left
panel
phenomenon
agreement
viral
np
express
profil
obtain
western
blot
analysi
similarli
dosedepend
reduct
viral
np
express
diphyllin
treatment
observ
cell
low
lm
diphyllin
pretreat
cell
result
reduct
viral
mrna
transcript
compar
untreat
control
fig
right
panel
ha
test
conduct
examin
releas
viral
particl
mdck
cell
supernat
mdck
cell
cultur
pretreat
lm
diphyllin
prior
viru
infect
reveal
significantli
lower
ha
titer
compar
untreat
control
fig
result
demonstr
diphyllin
dosedepend
antivir
effect
influenza
viru
influenza
viru
stabli
express
gfp
viru
replic
word
gfp
detect
virus
cell
unless
viral
replic
occur
therefor
imag
quantif
gfp
fluoresc
base
fluoresc
imag
use
evalu
extent
viru
entri
replic
seen
fig
refer
dapistain
nuclei
gfp
produc
viru
replic
observ
local
cytoplasm
gfp
fluoresc
reduc
pretreat
bafilomycin
increas
concentr
diphyllin
mdck
cell
quantif
gfp
fluoresc
rel
intens
test
well
demonstr
dosedepend
decreas
presenc
diphyllin
doserespons
curv
gfp
intens
found
diphyllintr
mdck
cell
shown
fig
valid
viral
inhibitori
effect
diphyllin
avian
influenza
viru
duck
isol
plaquepurifi
strain
also
test
result
show
viral
titer
dosedepend
reduc
diphyllin
treatment
particular
incub
lm
diphyllin
entir
abrog
growth
avian
influenza
viru
mdck
cell
fig
left
similar
dosedepend
viral
ha
titer
also
detect
fig
right
furthermor
context
infect
cell
dosedepend
reduct
extracelluar
fig
left
intracellular
fig
right
viral
titer
observ
diphyllin
treatment
compar
untreat
control
addit
viru
avian
influenza
viru
dengu
viru
serotyp
major
typessubtyp
human
influenza
viru
strain
also
employ
studi
test
antivir
effect
diphyllin
test
strain
includ
clinic
isol
season
pandem
two
refer
strain
type
b
influenza
viru
plaquepurifi
strain
indic
fig
diphyllin
treatment
lm
result
overal
dosedepend
reduct
viral
ha
titer
four
influenza
viru
strain
compar
untreat
control
result
suggest
diphyllin
possess
broadspectrum
antivir
activ
multipl
typessubtyp
influenza
virus
ic
diphyllin
amantadin
oseltamivir
variou
influenza
viru
strain
determin
cpe
inhibit
assay
result
list
tabl
diphyllin
exhibit
ic
valu
nanomolar
rang
test
viru
strain
among
valu
diphyllin
show
lowest
ic
nm
mean
sd
strain
rel
higher
ic
observ
strain
ic
nm
furthermor
clinic
isol
asan
carri
drugresist
mutat
na
gene
determin
dna
sequenc
data
shown
found
sensit
diphyllin
treatment
ic
nm
despit
viru
strong
resist
oseltamivir
ic
nm
similarli
show
resist
amantadin
ic
nm
sensit
diphyllin
ic
nm
antivir
activ
cpe
inhibit
provid
combinatori
treatment
evalu
studi
present
fig
combin
diphyllin
nm
oseltamivir
nm
result
enhanc
viral
np
reduct
compar
singledrug
treatment
compound
lower
amount
extracellular
viru
combin
treatment
also
confirm
ha
test
addit
combin
nm
diphyllin
indic
dose
oseltamivir
show
enhanc
cell
protect
influenza
viru
fig
instanc
dose
nm
oseltamivir
alon
result
cell
viabil
wherea
combinatori
treatment
nm
diphyllin
show
increas
cell
viabil
increas
dose
diphyllin
nm
improv
cell
viabil
superior
achiev
nm
oseltamivir
alon
cell
viabil
similar
enhanc
antivir
effect
cell
protect
observ
across
variou
dose
diphyllin
amantadin
combin
indic
fig
use
methodolog
assess
intracellularextracellular
viru
product
cpe
inhibit
combin
diphyllin
nm
amantadin
nm
demonstr
enhanc
inhibit
viral
np
express
viru
particl
releas
compar
individu
compound
treatment
fig
combinatori
addit
diphyllin
nm
amantadin
nm
also
increas
cell
viabil
viru
infect
indic
dose
fig
taken
togeth
combinatori
treatment
diphyllin
oseltamivir
diphyllin
amantadin
demonstr
enhanc
antivir
effect
cell
protect
diphyllin
one
newli
discov
vatpas
inhibitor
huss
wieczorek
includ
old
vatpas
inhibitor
bafilomycin
control
two
key
function
assay
similar
cellular
mechan
action
diphyllin
bafilomycin
observ
wide
varieti
structur
inhibitor
discov
includ
benzolacton
enamid
salicylihalamid
lobatamid
b
apicularen
indolyl
oximidin
macrolacton
archazolid
lobatamid
c
cruentaren
diphyllin
recent
report
synthet
compound
sb
huss
wieczorek
niikura
perezsayan
et
al
mani
vatpas
inhibitor
previous
evalu
antivir
activ
influenza
virus
guinea
carrasco
muller
et
al
ochiai
et
al
rhinovirus
suzuki
et
al
dengu
virus
duan
et
al
even
though
classic
vatpas
inhibitor
exhibit
potent
inhibitori
effect
influenza
virus
high
toxic
compound
made
unsuit
clinic
applic
drose
altendorf
niikura
muller
studi
instanc
bafilomycin
show
limit
therapeut
efficaci
vivo
despit
signific
viral
inhibit
vitro
implic
unselect
action
mechan
bafilomycin
exhibit
high
toxic
inflict
liver
spleen
damag
ngkg
contrast
structur
distinct
saliphenylhalamid
demonstr
effect
vivo
antivir
effect
mice
well
toler
dose
mgkg
improv
antivir
effecttox
profil
saliphenylhalamid
attribut
select
vatpas
inhibit
mechan
highlight
major
factor
consider
therapeut
applic
vatpas
inhibitor
regard
diphyllin
present
studi
compound
safeti
demonstr
previou
report
shen
et
al
daili
treatment
mice
dose
mgkg
toler
day
without
signific
sign
toxic
structur
saliphenylhalamid
diphyllin
fall
class
benzolacton
note
howev
saliphenylhalamid
lacton
salicyl
acid
diphyllin
lacton
naphthoic
acid
saliphenylhalamid
contain
macrocycl
nacyl
enamin
function
group
shown
requir
potent
vatpas
activ
lebreton
et
al
wherea
diphyllin
function
group
owe
multipl
isoform
vatpas
express
tissuespecif
manner
toei
et
al
therapeut
use
vatpas
inhibitor
reli
select
inhibit
niikura
although
tissu
isoform
specif
inhibit
diphyllin
yet
determin
diphyllin
studi
demonstr
safe
therapeut
window
two
type
mammalian
cell
line
ic
valu
virus
nanomolar
rang
nm
cellular
cytotox
micromolar
rang
lm
suggest
potenti
role
vivo
studi
believ
broadspectrum
antivir
agent
high
potenc
low
toxic
may
develop
exist
compound
deriv
effect
diphyllin
endosom
acidif
monitor
vital
stain
acridin
orang
use
scan
flow
cytometri
agreement
previou
work
human
osteoclast
cell
cultur
sorensen
et
al
diphyllin
dosedepend
quench
acid
cytoplasm
vesicl
within
short
period
period
infect
cell
wash
overlaid
fresh
media
contain
concentr
diphyllin
previou
step
incub
anoth
h
cell
cultur
supernat
harvest
tcid
assay
left
ha
test
right
respect
b
cell
treat
diphyllin
use
procedur
inocul
infect
moi
twentyfour
hour
later
cultur
supernat
cell
harvest
determin
viru
titer
use
plaqu
assay
left
realtim
quantit
rtpcr
right
respect
valu
mean
sd
three
replic
viral
titer
treat
group
untreat
control
group
compar
oneway
anova
follow
dunnett
multipl
comparison
test
ns
nonsignific
p
p
p
p
incub
time
min
mdck
cell
observ
support
diphyllin
could
interfer
low
phdepend
membran
fusion
viru
intracellular
endosom
infect
studi
gfpexpress
influenza
viru
signific
inhibitori
effect
obtain
pretreat
protocol
indic
prior
exposur
diphyllin
alter
suscept
cell
influenza
viru
regul
amount
acidifi
endosom
within
cell
meanwhil
two
test
timeofaddit
diphyllin
also
exhibit
inhibitori
effect
virus
compar
mocktreat
group
suggest
concurr
treatment
diphyllin
upon
viru
replic
might
worthwhil
altern
prophylaxi
feasibl
owe
vast
number
viru
strain
circul
worldwid
seek
drug
univers
effect
influenza
virus
regardless
viral
typesubtyp
studi
besid
laboratori
strain
resist
amantadin
scholtissek
faulkner
ic
amantadin
higher
lm
test
avian
influenza
viru
five
typessubtyp
viru
strain
tabl
includ
oseltamivirresist
clinic
isol
san
ic
oseltamivir
higher
lm
result
clearli
show
diphyllin
demonstr
cpe
protect
inhibit
influenza
viral
replic
multipl
typessubtyp
includ
drugresist
strain
investig
spectrum
antivir
activ
diphyllin
extend
use
diphyllin
context
dengu
viru
anoth
emerg
human
pathogen
share
similar
phdepend
viru
entri
mechan
influenza
virus
pierson
diamond
result
show
diphyllin
interf
dengu
viru
replic
cell
support
notion
diphyllin
valu
mean
sd
three
replic
viral
titer
treat
group
untreat
control
group
compar
oneway
anova
follow
dunnett
multipl
comparison
test
ns
nonsignific
p
p
p
p
ic
concentr
compound
show
inhibit
virusinduc
cell
cytopath
effect
mean
sd
b
nt
test
possess
hosttarget
strainindepend
mechan
inhibit
also
multipl
method
use
studi
evalu
diphyllin
effect
includ
assay
infect
investig
viral
mrna
transcript
qrtpcr
protein
express
western
blot
examin
gfp
express
surrog
readout
viru
replic
cpe
protect
quantif
extracellular
viru
particl
use
ha
test
corrobor
antivir
effect
diphyllin
combinatori
effect
diphyllin
also
studi
combin
commerci
avail
na
inhibitor
oseltamivir
ion
channel
blocker
amantadin
diphyllin
combin
diphyllin
amantadin
show
enhanc
inhibitori
effect
viru
express
cpe
protect
given
amantadin
function
inhibit
protonpump
viral
antigen
ciampor
et
al
therebi
regul
vesicular
ph
analog
fashion
diphyllin
cooper
amantadin
diphyllin
presum
due
complet
inhibit
endosom
acidif
occur
two
drug
combin
hand
sinc
diphyllin
take
effect
earli
stage
replic
cycl
viru
fusionunco
oseltamivir
take
effect
later
stage
replic
cycl
releas
viron
infect
cell
combin
two
drug
hypothes
result
synergist
action
expect
viral
protein
express
ha
titer
significantli
reduc
combin
two
drug
given
compar
singledrug
treatment
enhanc
activ
oseltamivir
cpe
protect
also
observ
combin
diphyllin
report
cellbas
assay
less
advantag
direct
enzymat
measur
na
monitor
suscept
na
inhibitor
tisdal
experiment
set
howev
aim
compar
combinatori
effect
diphyllin
na
inhibitor
rather
measur
suscept
virus
certain
na
inhibitor
moreov
due
differ
sensit
assay
method
util
studi
dose
compound
combin
preoptim
reflect
dynam
rang
demonstr
appreci
interact
differ
compound
instanc
higher
dose
compound
use
western
blot
ha
test
fig
compar
use
cpe
assay
fig
contrast
commonli
use
oseltamivir
note
amantadin
current
recommend
antivir
treatment
chemoprophylaxi
human
influenza
extens
resist
observ
among
viral
strain
fior
et
al
present
studi
show
diphyllin
enhanc
amantadin
antivir
effect
may
aid
current
effort
restor
amantadin
activ
amantadineresist
influenza
viru
strain
use
combin
treatment
nguyen
et
al
addit
antivir
effect
amantadin
demonstr
equin
influenza
timoney
van
maanen
cullinan
possess
therapeut
valu
veterinari
medicin
influenza
virus
undergo
rapid
mutat
difficult
predict
drug
sensit
new
gener
virus
drug
combin
diphyllin
vatpas
inhibitor
present
valuabl
strategi
help
combat
antivir
resist
summari
herein
demonstr
diphyllin
novel
natur
potent
vatpas
inhibitor
alter
cellular
suscept
b
fig
combin
diphyllin
oseltamivir
show
enhanc
antivir
effect
cpe
protect
diphyllin
nm
oseltamivir
nm
use
individu
combin
viru
infect
mdck
cell
describ
section
cell
harvest
np
express
analysi
use
western
blot
extracellular
viru
titer
supernat
determin
ha
test
b
oseltamivir
nm
use
absenc
presenc
diphyllin
nm
viru
infect
mdck
cell
describ
section
mtt
assay
perform
normal
cell
viabil
present
valu
mean
sd
three
replic
cell
viabil
diphyllin
cooper
treat
group
amantadin
alon
treat
group
compar
twoway
anova
follow
dunnett
multipl
comparison
test
ns
nonsignific
p
p
p
p
influenza
virus
inhibit
endosom
acidif
lead
abrog
viru
replic
cell
combinatori
treatment
hosttarget
diphyllin
pathogentarget
therapeut
oseltamivir
amantadin
demonstr
enhanc
antivir
effect
cell
protect
vitro
vivo
use
diphyllin
await
investig
use
anim
model
amantadin
nm
use
individu
combin
viru
infect
mdck
cell
describ
section
cell
harvest
np
express
analysi
use
western
blot
extracellular
viru
titer
supernat
determin
ha
test
b
amantadin
nm
use
absenc
presenc
diphyllin
nm
viru
infect
mdck
cell
describ
section
mtt
assay
perform
normal
cell
viabil
present
valu
mean
sd
three
replic
cell
viabil
diphyllin
cooper
treat
group
amantadin
alon
treat
group
compar
twoway
anova
follow
dunnett
multipl
comparison
test
ns
nonsignific
p
p
p
p
